Y.S.P. Southeast Asia Holding Bhd (XKLS:7178) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Y.S.P. Southeast Asia Holding Bhd EBITDA Margin % Related Terms
Y.S.P. Southeast Asia Holding Bhd EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Y.S.P. Southeast Asia Holding Bhd EBITDA Margin % Chart
XKLS:7178 vs ZTS, UTHR, VTRS: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Y.S.P. Southeast Asia Holding Bhd's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Y.S.P. Southeast Asia Holding Bhd EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Y.S.P. Southeast Asia Holding Bhd's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Y.S.P. Southeast Asia Holding Bhd's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Y.S.P. Southeast Asia Holding Bhd (XKLS:7178) has a EBITDA Margin % of 14.47% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Y.S.P. Southeast Asia Holding Bhd and its competitors. This is 10% below median its historical median of 16.13. Over the past decade, Y.S.P. Southeast Asia Holding Bhd's EBITDA Margin % has ranged from 10.48 to 20.21. According to the industry distribution chart, Y.S.P. Southeast Asia Holding Bhd ranks #529 out of 952 companies in the Drug Manufacturers industry, placing it in the top 55.6%.
Is Y.S.P. Southeast Asia Holding Bhd's EBITDA Margin % too high?
Y.S.P. Southeast Asia Holding Bhd's current EBITDA Margin % of 14.47% is 10% below median its 10-year median of 16.13. Over the past 10 years, this metric has ranged from a low of 10.48 to a high of 20.21. The Drug Manufacturers industry median EBITDA Margin % is 12.47. Y.S.P. Southeast Asia Holding Bhd's value of 14.47% is 16% above this industry median. Based on the distribution chart, Y.S.P. Southeast Asia Holding Bhd ranks #529 out of 952 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Y.S.P. Southeast Asia Holding Bhd has a GF Score™ of 82/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Y.S.P. Southeast Asia Holding Bhd's EBITDA Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Y.S.P. Southeast Asia Holding Bhd ranks #529 out of 952 companies for EBITDA Margin %. This places Y.S.P. Southeast Asia Holding Bhd in the lower half of its industry. The industry median EBITDA Margin % is 12.47. Y.S.P. Southeast Asia Holding Bhd's value of 14.47% is 16% above this benchmark. Historically, Y.S.P. Southeast Asia Holding Bhd's own EBITDA Margin % has ranged from 10.48 to 20.21 over the past decade. While the company's 10-year median is 16.13 vs. the industry median of 12.47, Y.S.P. Southeast Asia Holding Bhd has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.47, based on 952 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Y.S.P. Southeast Asia Holding Bhd's current EBITDA Margin % of 14.47% is 16% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Y.S.P. Southeast Asia Holding Bhd and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Y.S.P. Southeast Asia Holding Bhd's current EBITDA Margin % is 14.47%, which is 10% below median its own 10-year median of 16.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Y.S.P. Southeast Asia Holding Bhd stock overvalued right now?
Based on GuruFocus' analysis, Y.S.P. Southeast Asia Holding Bhd (XKLS:7178) is currently considered Modestly Undervalued. The stock's GF Value™ is RM2.40, compared to a current price of RM2.04 — trading 15% below its estimated fair value. The current EBITDA Margin % is 14.47%, which is 10% below median its 10-year median of 16.13 and 16% above the Drug Manufacturers industry median of 12.47. Y.S.P. Southeast Asia Holding Bhd's overall GF Score™ is 82/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Y.S.P. Southeast Asia Holding Bhd (XKLS:7178), the current EBITDA Margin % is 14.47% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Y.S.P. Southeast Asia Holding Bhd (XKLS:7178) Overvalued in 2026?
Based on GuruFocus' analysis, Y.S.P. Southeast Asia Holding Bhd stock appears to be undervalued.
The current stock price of RM2.04 is trading 15% below its estimated GF Value™ of RM2.40.
GuruFocus considers Y.S.P. Southeast Asia Holding Bhd to be Modestly Undervalued.
Key valuation signals for XKLS:7178:
EBITDA Margin %: 14.47% (10% below median its 10-year median of 16.13)
GF Value™: RM2.40 vs. price of RM2.04 (15% below fair value)
Industry Position: 16% above the Drug Manufacturers median (#529 of 952)
No single metric tells the full story. See the XKLS:7178 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Y.S.P. Southeast Asia Holding Bhd Business Description
Y.S.P. Southeast Asia Holding Bhd is an investment company, that engages in the pharmaceutical business, and provision of management services. The company operates through the following segments: Trading, Manufacturing, and Investment Holding. The Trading segment imports, exports, and trading in various kinds of pharmaceutical products, and traditional herbal and veterinary products. The Manufacturing segment manufactures pharmaceutical products. The Investment Holding segment focuses on investment holding activity. The firm's majority of revenue comes from the Manufacturing segment. The majority of revenue is derived from Malaysia.
82GF Score
Get the complete analysis for XKLS:7178
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XKLS:7178 has been successfully added to your 
